source
- VectorY Therapeutics raises $83.5M Series A to develop brain-targeted antibody gene therapyVectorY Therapeutics announced it has closed a Series A financing round, adding €74.5 million ($83.5 million) to its capital. The funds will be used to advance its lead gene-therapy candidate VTx-…
- Neurosterix raises $105 million Series B to advance schizophrenia candidateNeurosterix announced it has closed a $105 million Series B financing round. The capital will be used to develop its lead drug candidate for schizophrenia, which targets a pathway also addressed by…